Scienture Holdings SCNX
NASDAQ SCNX
$0.37 +0.01 (+1.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scienture Holdings (SCNX) Price to Sales (2025 - 2026)

Scienture Holdings' (SCNX) quarterly Price to Sales came in at 41.82 in Q2 2026, down 79.66% quarter-over-quarter from 205.59 in Q1 2026.

Analysis

Scienture Holdings (SCNX) Price to Sales (2025 - 2026) Analysis & Trends

Scienture Holdings has disclosed Price to Sales across 2 years of filings, most recently posting 41.82 for Q2 2026.

  • In Q2 2026, Price to Sales changed N/A year-over-year to 41.82; the TTM figure through Jun 2026 stood at 35.04 (up 1045.42% YoY), while the FY2025 annual figure was 18.13, down 87.87% from the prior year.
  • Price to Sales came in at 41.82 for Q2 2026 at Scienture Holdings, down from 205.59 in the prior quarter.
  • In the past five years, Price to Sales ranged from a high of 1323.17 in Q1 2025 to a low of 41.82 in Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 42.34 Bn 38.68 Bn 2.15 Bn
2 Viatris 19.39 Bn 18.50 Bn 1.46 Bn
3 Dr Reddys Laboratories 9.99 Bn 9.85 Bn 396.53 Mn
4 Amneal Pharmaceuticals 5.57 Bn 5.53 Bn 334.51 Mn
5 Bausch Health Companies 2.45 Bn 1.58 Bn 2.10 Bn
6 Ani Pharmaceuticals 1.70 Bn 1.34 Bn 165.89 Mn
7 Alvotech 1.66 Bn 1.52 Bn 2.56 Mn
8 Amphastar Pharmaceuticals 985.90 Mn 695.77 Mn 93.47 Mn
9 Fennec Pharmaceuticals 434.07 Mn 392.82 Mn 17.15 Mn
10 Scienture Holdings 15.19 Mn 15.19 Mn 335,779.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 41.82
Mar 31, 2026 205.59
Mar 31, 2025 1,323.17